ELUVIATM DRUG-ELUTING VASCULAR STENT SYSTEM 24620

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a company representative,foreig report with the FDA on 2020-03-11 for ELUVIATM DRUG-ELUTING VASCULAR STENT SYSTEM 24620 manufactured by Boston Scientific Corporation.

Event Text Entries

[183012939] Device is a combination product.
Patient Sequence No: 1, Text Type: N, H10


[183012940] It was reported that stent thrombosis occurred. The subject was enrolled in the imperial study on (b)(6) 2016 and the index procedure was performed on the same day. Target lesion was in the left proximal superficial femoral artery (sfa) extending to mid sfa with 100% stenosis and was 190 mm long with a proximal reference vessel diameter of 5. 5 mm and distal vessel diameter of 5. 2 mm and was classified as tasc ii c lesion. The target lesion was treated with pre-dilatation and placement of two 6 mm x 150 mm and 6 mm x 100 mm study stents respectively. Following post-dilatation, residual stenosis was 0%. On (b)(6) 2016, the subject was discharged on aspirin and clopidogrel. On (b)(6) 2020, the subject visited the hospital as an outpatient and subsequently vascular ultrasound of both lower extremity arteries was performed which revealed a right limb: stenosis in iliac area; mild stenosis was noted in common femoral artery (cfa) and sfa to popliteal artery. The left limb was moderate to severe stenosis in cia; moderate stenosis in cfa; occlusion of stent noted from proximal to distal sfa. Based upon above findings, no action was taken at that point of time and the subject was scheduled for endovascular treatment on (b)(6) 2020. On (b)(6) 2020, the subject was hospitalized for scheduled treatment. On the same day, 1162 days post procedure, 100% in stent occlusion noted in left sfa was treated by performing percutaneous intervention where the target lesion was initially predilated with a 4. 0 x 150 mm non-bsc study stent followed by additional dilation with a 5. 0 x 150 mm non-bsc study stent. Post dilatation, the poor site of dilation in the stent was treated by performing hyperbaric dilation added with a 5. 0 x 20 mm cutting balloon. Finally, long time dilation was performed twice with a 6. 0 x 150 mm non-bsc drug coated balloon with 0% residual stenosis (tvr). On (b)(6) 2020, the event was considered resolved and the subject was discharged on the same day. No further information is available at this point of time.
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report Number2134265-2020-02912
MDR Report Key9818791
Report SourceCOMPANY REPRESENTATIVE,FOREIG
Date Received2020-03-11
Date of Report2020-03-11
Date of Event2020-01-08
Date Mfgr Received2020-02-20
Device Manufacturer Date2016-01-29
Date Added to Maude2020-03-11
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactJAY JOHNSON
Manufacturer StreetTWO SCIMED PLACE
Manufacturer CityMAPLE GROVE MN 55311
Manufacturer CountryUS
Manufacturer Postal55311
Manufacturer Phone7634942574
Manufacturer G1BOSTON SCIENTIFIC SCIMED, INC
Manufacturer StreetTWO SCIMED PLACE
Manufacturer CityMAPLE GROVE MN 55311
Manufacturer CountryUS
Manufacturer Postal Code55311
Single Use3
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NameELUVIATM DRUG-ELUTING VASCULAR STENT SYSTEM
Generic NameSTENT, SUPERFICIAL FEMORAL ARTERY, DRUG-ELUTING
Product CodeNIU
Date Received2020-03-11
Model Number24620
Catalog Number24620
Lot Number0018822231
Device Expiration Date2017-01-31
OperatorHEALTH PROFESSIONAL
Device AvailabilityN
Device Eval'ed by MfgrR
Device Sequence No1
Device Event Key0
ManufacturerBOSTON SCIENTIFIC CORPORATION
Manufacturer AddressTWO SCIMED PLACE MAPLE GROVE MN 55311 US 55311


Patients

Patient NumberTreatmentOutcomeDate
101. Required No Informationntervention 2020-03-11

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.